Panel – Bench to Bedside & Back – Assessing the Benefits of a Reverse Translational Approach When Minimizing ADC Toxicities
Time: 12:00 pm
day: Conference Day 2
Details:
- Viewing the ways toxicities present themselves clinically to consider what can be done preclinically to mitigate these effects
- Transferring from human studies to animal studies to obtain a deeper understanding of how different ADCs are distributed across healthy tissues
- Understanding potential biomarkers for predicting toxicities which present in humans and being able to connect this back to the pre-clinical stage
- Navigating the concept of translating back and mechanistically blocking the toxicity in vitro
